Key facts
- Confocal NL’s last known valuation is $12.9M (Jul 2022).
- It has raised $8.5M; the latest was PE Growth/Expansion in Jul 2025.
- Notable investors include Innovatiefonds Noord-Holland, Rijksdienst voor Ondernemend Nederland, Attract EU, Coöperatieve Rabobank, ECFG — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Confocal NL
- ·The full record, as it builds
Funding rounds
No funding rounds for Confocal NL are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Confocal NL
Developer of plug-and-play confocal microscopes committed to improving the microscopy imaging experience of researchers around the world. The company's laser scanning confocal system with the re-scanning confocal microscopy (RCM) technology allows enhanced resolution in combination with low laser intensity, thereby helping its users by making confocal technology without extensive microscopy experience.
- Sector
- Healthcare
- HQ
- Amsterdam, Netherlands
- Founded
- 2013
- Employees
- 17
- Website
- confocalnl.com/
- Ownership
- Privately Held (backing)
Confocal NL doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Confocal NL shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Confocal NL in its N-PORT filings yet. We sweep new filings monthly.